Jihao Zhou, M.D., Ph.D.

Jihao Zhou, M.D., Ph.D., is the vice president and head of biometrics at BlossomHill Therapeutics. Dr. Zhou has more than two decades of experience in the biopharmaceutical industry and is a seasoned leader in clinical drug development, primarily focusing on biometrics. Prior to joining BlossomHill Therapeutics, Dr. Zhou served as the vice president of clinical development at Autobahn Therapeutics. Prior to that, Dr. Zhou served as the vice president and head of data sciences at AnaptysBio, Inc., where he provided strategic leadership and analysis for product development across broad therapeutic pipelines. This includes the successful Phase 3 development of imsidolimab in generalized pustular psoriasis.

Throughout Dr. Zhou’s career, he’s held notable, impactful roles at Urovant Sciences, Allergan and Pfizer, where he and his team made significant contributions to the development and approval of new pharmaceutical products. This includes Pfizer’s blockbuster oncology drug sunitinib (SUTENT^®), Allergan’s botulinum toxin (BOTOX^®) for therapeutic indications and Urovant’s vibegron (GEMTESA^®) for OAB, among others. Dr. Zhou’s innovation in clinical drug development is exhibited through his involvement as an inventor and co-inventor in patent applications in multiple medical fields.

Dr. Zhou received an Doctor of Medicine from Peking Union Medical College in Beijing and completed a postdoctoral fellowship at the University of Münster in Germany. He then received a doctorate in biostatistics from the University of Michigan, Ann Arbor.